Table 1.
Comparison of patient characteristics between AML with NUP98-r and those without NUP98-r
| Characteristics | Patients with NUP98-r (n = 9) | Patients without NUP98-r (n = 133) | P value |
|---|---|---|---|
| Male, n (%) | 6 (66.7%) | 87 (65.4%) | 0.775 |
| Age, M (range) years | 4.4 (1.5–14.2) | 5.9 (0.3–18.0) | 0.864 |
| WBC, M (range) × 109/L | 34.4 (3.3–375.2) | 15.8 (1.1–557.2) | 0.273 |
| Hb, M (range) × g/L | 94.0 (36.0–107.0) | 88.5 (22.0–135.0) | 0.826 |
| PLT, M (range) × 109/L | 90.0 (10.0–595.0) | 62.0 (2.0–571.0) | 0.607 |
| BM blast (%) | 75.0 (38.0–92.0) | 69.5 (9.0–97.0) | 0.717 |
| Immunotyping | |||
| CD33+ | 9/9 (100%) | 117/127 (92.1%) | 1.000 |
| CD13+ | 6/9 (66.7%) | 86/127 (67.7%) | 0.761 |
| MPO+ | 4/9 (44.4%) | 57/127 (44.9%) | 0.748 |
| CD117+ | 7/9 (77.8%) | 106/127 (83.5%) | 0.984 |
| HLA-DR+ | 6/9 (66.7%) | 103/126 (81.7%) | 0.502 |
| CD34+ | 6/9 (66.7%) | 69/127 (54.3%) | 0.710 |
| CD11b+ | 2/9 (22.2%) | 41/127 (32.3%) | 0.798 |
| CD45+ | 9/9 (100%) | 125/127 (98.4%) | 1.000 |
| CD15+ | 4/9 (44.4%) | 74/127 (58.3%) | 0.644 |
| CD4+/CD7+ | 4/9 (44.4%) | 67/127 (52.8%) | 0.891 |
| CD56+ | 1/9 (11.1%) | 46/126 (36.5%) | 0.237 |
| Morphology | |||
| M0 | 0 (0%) | 5 (3.8%) | 1.000 |
| M1 | 0 (0%) | 2 (1.5%) | 1.000 |
| M2 | 4 (44.4%) | 44 (33.1%) | 0.739 |
| M4 | 1 (11.1%) | 17 (12.8%) | 0.710 |
| M5 | 3 (33.3%) | 62 (46.6%) | 0.668 |
| M6 | 0 (0%) | 1 (0.8%) | 1.000 |
| M7 | 0 (0%) | 2 (1.5%) | 1.000 |
| APL-like | 1 (11.1%) | 0 (0.0%) | 0.063 |
| Cytogenetics | |||
| Normal karyotype | 5/9 (55.6%) | 30/131 (22.6%) | 0.073 |
| Complex karyotype | 3/9 (33.3%) | 17/131 (12.8%) | 0.232 |
AML acute myeloid leukemia, NUP98-r NUP98 rearrangement, WBC white blood cell, HB haemoglobin, PLT platelet, BM bone marrow